Veverimer:慢性肾脏病代谢性酸中毒的新兴潜在治疗选择
本文综述了Veverimer(TRC101)这一新型非吸收性聚合物在慢性肾脏病代谢性酸中毒中的研究证据。该药在胃肠道结合氢离子和氯离子并经粪便排出,从而在不增加钠负荷的情况下提高血清碳酸氢盐浓度。文章还探讨了其非剂量依赖性效应及等氯性碳酸氢盐升高伴阴离子间隙降低等意外发现,并提出了可能解释。
要点
- Veverimer是一种非吸收性聚合物,通过结合并排出HCl提高血清碳酸氢盐,不增加钠负荷。
- 研究显示Veverimer可提高血清碳酸氢盐并改善躯体功能,安全性记录良好。
- 其升高碳酸氢盐呈非剂量依赖性,且为等氯性升高伴阴离子间隙降低,机制待阐明。
核心结论
- Veverimer在不增加钠负荷的情况下提高慢性肾脏病代谢性酸中毒患者的血清碳酸氢盐浓度,并可能改善躯体功能。
研究设计与样本
- 本文为综述,检索并分析已发表的关于Veverimer在慢性肾脏病代谢性酸中毒患者中研究性使用的证据。
主要发现
- Veverimer提高血清碳酸氢盐浓度,且不伴随钠的给予。
- Veverimer对躯体功能有改善作用,并具有良好的安全性记录。
- 血清碳酸氢盐升高缺乏剂量依赖性。
- 尽管推测粪便中HCl丢失量大,Veverimer引起等氯性血清碳酸氢盐升高并伴随血清阴离子间隙降低。
临床怎么用
- 对于合并高血压或钠潴留状态而不宜使用碳酸氢钠的慢性肾脏病代谢性酸中毒患者,Veverimer可能提供一种不增加钠负荷的治疗选择。
局限性
- Veverimer的作用机制尚不明确,尤其是非剂量依赖性效应和等氯性升高伴阴离子间隙降低的原因。
- Veverimer与结肠菌群之间可能存在的相互作用尚未阐明。
- 需要进一步研究填补这些可能具有重要临床意义的知识空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sodium bicarbonate is the mainstay treatment of the metabolic acidosis of chronic kidney disease but associated concerns center on administering sodium to patients with hypertension and sodium-retentive states. Veverimer (formerly referred to as TRC101), a drug candidate for which Tricida, Inc is seeking approval from the US Food and Drug Administration, is a novel nonabsorbable polymer that binds hydrogen cations and chloride anions in the gastrointestinal tract and then is excreted fecally, thereby increasing serum bicarbonate concentration without administering sodium. We examine the published evidence on the investigational use of veverimer in patients with chronic kidney disease and metabolic acidosis. We highlight the achieved increase in serum bicarbonate concentration without coadministering sodium, effects on physical functioning, and the safety record of the drug. We also scrutinize certain unanticipated findings: a lack of dose dependency in the increase in serum bicarbonate concentration observed and that despite the presumed large hydrogen chloride losses in feces, veverimer induces an isochloremic increase in serum bicarbonate concentration that is accompanied by a decrease in serum anion gap. We propose likely explanations for these puzzling findings and raise questions about veverimer's mode of action and its potential interaction with colonic bacterial flora. Additional work is required to fill these knowledge gaps that could have important clinical implications.
引用
- Adrogué HJ, Madias NE. Veverimer: An Emerging Potential Treatment Option for Managing the Metabolic Acidosis of CKD. Am J Kidney Dis. 2020. PMID: 32920151. doi:10.1053/j.ajkd.2020.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。